Intriguingly, despite the development of another BH3 mimetic Obatoclax (GX15-070), which can also target MCL-1 in addition to BCL-2 and BCL-XL, and with its efficacy tested in various adult cancers [127], its effectiveness in childhood cancers was, nevertheless, not well-studied. This evidence concerns the gene BCL2L1 and childhood malignant neoplasm.